<table border="1" id="table_7" rules="all" width="0.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_09220324-a0ce-45b8-ba75-c8dfb39f14c4">Table 3. Paricalcitol Capsule Pharmacokinetic Characteristics in CKD Stages 3, 4, and 5 Patients</caption>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<tbody>
<tr id="id_a64b6b7a-51fa-4dbe-858e-6523f47e99ea">
<td align="left" stylecode="Lrule Toprule" valign="top">
<content stylecode="bold">Pharmacokinetic Parameters</content>
</td>
<td align="center" stylecode="Toprule" valign="top">
<content stylecode="bold">CKD Stage 3<br/>n = 15*</content>
</td>
<td align="center" stylecode="Toprule" valign="top">
<content stylecode="bold">CKD Stage 4<br/>n = 14*</content>
</td>
<td align="center" stylecode="Toprule" valign="top">
<content stylecode="bold">CKD Stage 5 HD**<br/>n = 14</content>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">CKD Stage 5 PD**<br/>n = 8</content>
</td>
</tr>
<tr id="id_200ac9f0-9945-432e-ac31-0315523dd322">
<td align="left" stylecode="Lrule" valign="top">C<sub>max</sub> (ng/mL)</td>
<td align="center" valign="top">0.11 ± 0.04</td>
<td align="center" valign="top">0.06 ± 0.01</td>
<td align="center" valign="top">0.575 ± 0.17</td>
<td align="center" stylecode="Rrule" valign="top">0.413 ± 0.06</td>
</tr>
<tr id="id_d088a973-b196-42ef-9249-02e46d69b810">
<td align="left" stylecode="Lrule" valign="top">AUC<sub>0-∞</sub> (ng<content stylecode="bold">•</content>h/mL)</td>
<td align="center" valign="top">2.42 ± 0.61</td>
<td align="center" valign="top">2.13 ± 0.73</td>
<td align="center" valign="top">11.67 ± 3.23 </td>
<td align="center" stylecode="Rrule" valign="top">13.41 ± 5.48</td>
</tr>
<tr id="id_822b1a72-441c-43bd-ad0a-65a738c37eb0">
<td align="left" stylecode="Lrule" valign="top">CL/F (L/h)</td>
<td align="center" valign="top">1.77 ± 0.50</td>
<td align="center" valign="top">1.52 ± 0.36</td>
<td align="center" valign="top">1.82 ± 0.75 </td>
<td align="center" stylecode="Rrule" valign="top">1.76 ± 0.77</td>
</tr>
<tr id="id_9038a298-0dfa-4bfb-b05f-2ba8d852375d">
<td align="left" stylecode="Lrule" valign="top">V/F (L)</td>
<td align="center" valign="top">43.7 ± 14.4</td>
<td align="center" valign="top">46.4 ± 12.4</td>
<td align="center" valign="top">38 ± 16.4 </td>
<td align="center" stylecode="Rrule" valign="top">48.7 ± 15.6</td>
</tr>
<tr id="id_f77da460-d425-4f67-a09b-81cc3c7e27c9">
<td align="left" stylecode="Lrule" valign="top">t<sub>1/2</sub>
</td>
<td align="center" valign="top">16.8 ± 2.65</td>
<td align="center" valign="top">19.7 ± 7.2</td>
<td align="center" valign="top">13.9 ± 5.1</td>
<td align="center" stylecode="Rrule" valign="top">17.7 ± 9.6</td>
</tr>
<tr id="id_7cfd61a6-808d-493c-90a5-4ac5acff1a33">
<td align="left" colspan="5" stylecode="Lrule Botrule Rrule" valign="top">* Four mcg paricalcitol capsules were given to CKD Stage 3 patients; three mcg paricalcitol capsules were given to CKD Stage 4 patients.<br/>** CKD Stage 5 HD and PD patients received a 0.24 mcg/kg dose of paricalcitol as capsules.</td>
</tr>
</tbody>
</table>